Introduction to Translational Medicine

When: May 10, 2018

Venue: SingHealth Academia

Event Description:

Translational medicine can be defined as the continuum from a scientific idea or finding to a diagnostic tool and/or therapy applied to human diseases. The field of translational medicine encompasses molecular medicine, intellectual property, financing, regulation, preclinical and clinical trial studies, among other disciplines. Translational Medicine has emerged as a discipline central to the goal of converting basic science discoveries to diagnostic and therapeutic tools that can be harnessed to treat disease and improve human health.

Speakers

Dr. Stuart Cook

Dr. Stuart Cook grew up in Kenya, went to high school at St Edward’s, Oxford and studied medicine at St Bartholomew’s Medical School, London. He did a PhD at the National Heart and Lung Institute, UK and a Postdoctoral Fellowship at Harvard. He trained in cardiology and sub-specialized in cardiac MRI. He is Professor at Imperial College, London and Duke-National University of Singapore (Duke-NUS). He is a cardiologist at the National Heart Centre Singapore where he oversees the clinical MRI service. He is the Director of the National Heart Research Institute Singapore and Program Director of the CVMD program at Duke-NUS. He is co-founder of Enleofen, a biotechnology company developing therapies for the treatment of fibrotic diseases.

Mr. Lin XiangLiang

Mr. XiangLiang (XL) Lin is the Founder & President of Esco Healthcare, a division of Esco Group of Companies. Esco boasts its strength of multiple manufacturing sites across the globe. XL also designed and oversaw the engineering, manufacturing and validation of the company’s first cGMP-compliant isolators, downflow booths, bioreactors, and clean air & containment technology.Esco transitioned from tools provider to on-site process development and with its developed technologies, Esco Aster was formed in 2018. Today, Esco Aster is the leading independent Contract Development and Manufacturing Organization (CDMO).

XL Lin graduated with a degree in Bachelor of Sciences from University of Sydney and has plans to further his studies.

Professor Salvatore Albani

Professor Salvatore Albani, Professor at Duke-NUS Graduate Medical School Singapore, Director of the Translational Immunology Institute, and Senior Clinical Scientist with the Paediatrics Academic Clinical Program. Professor Albani is an internationally renowned rheumatologist and immunologist. His fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. He developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from idea to conclusion of Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals. This translational research itinerary has been the original backbone of his career, as witnessed by a rich publication trail (among others Nature Medicine, Lancet, JCI, PNAS, Nature Rheumatology, A&R, ARD, etc) and by approximately 100 patents, disclosures and applications.